心血管生物標誌企業・製品・展望

Abstract

Part of Espicom' s new 3-volume report on Cancer, CNS and Cardiovascular Biomarkers, this volume provides a comprehensive analysis of the cardiovascular biomarker sector, along with a critical assessment of the companies involved.

Table of Contents

EXECUTIVE SUMMARY

• Figure1: Growth in biomarker market 2007-2015
• What are biomarkers?
• Why are they important?
• Figure 2: Potential impact of biomarkers on disease pathways
• What technologies are involved?
• What impact will biomarkers have on R&D?
• Figure 3: Potential impact of biomarkers on R&D
• Who are the major biomarker players and in what research area?
• Cancer biomarker companies
• Cardiovascular biomarker companies
• CNS biomarkers companies
• Company Analysis Criteria
  • Biomarker technology & platforms
  • Association/clinical studies
  • Management strategy
  • Application & potential

CARDIOVASCULAR MARKET & REVENUES

• Market revenues - global
  • Figure 1: Global cardiovascular disease drug sales 2007
• Market revenues - leading brands
  • Figure 2: Leading Cardiovascular brands (2007)
• Market revenues - leading players
  • Figure 3: Top 10 cardiovascular players (2007 revenues)

CARDIOVASCULAR EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT

• Epidemiology
  • Figure 4: Breakdown of deaths from cardiovascular diseases in the US (2004)
• Diagnosis
• Screening
  • Table 1: Screening for cardiovascular disease
• Current treatments
  • Table 2: Cardiovascular therapeutic drug categories and their indications
• Future treatments
  • Figure 5: Drugs in clinical development for heart disease

CARDIOVASCULAR BIOMARKERS

• Cardiovascular biomarker R&D
  • Figure 6: Impact of biomarkers on the drug R&D process
  • Table 3: Types of biomarker
• Known cardiovascular biomarkers
  • Table 4: Commercially available cardiovascular diagnostics
• Probable and possible valid cardiovascular biomarkers
  • Table 5: Probable cardiovascular biomarkers
  • Table 6: Possible cardiovascular biomarkers

CARDIOVASCULAR BIOMARKER OPPORTUNITIES & CHALLENGES

• Opportunities
  • Figure 7: Cardiovascular biomarker opportunities
• Challenges
  • Figure 8: Cardiovascular biomarker challenges

BIOMARKER MARKET

• Biomarker market revenues - global
  • Figure 9: Global biomarker sales in 2007
• Cardiovascular biomarker market revenues - global
  • Figure 10: Global cardiovascular biomarker sales in 2007
• Future biomarker market revenues - global
  • Figure 11: Global biomarker sales in 2015
• Future cardiovascular biomarker market revenues - global
  • Figure 12: Global cardiovascular biomarker sales in 2015

CARDIOVASCULAR BIOMARKER TRENDS

• Table 7: Recent deals in cardiovascular biomarkers
• Pharma and specialty pharma deals
• Collaborations with service providers
• Collaborations with academics and consortia

BIOMARKER ANALYSIS

• Assays for circulating biomarkers
• DNA and RNA biomarkers
• Proteomic, metabolomic biomarkers
• Systems biology for biomarker discovery
• Imaging biomarkers

KEY BIOMARKER COMPANIES ANALYSED

KEY BIOMARKER EVALUATION CRITERIA

CARDIOVASCULAR BIOMARKERS - COMPANY ANALYSIS

Abbott Diagnostics

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Atherotech

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Affymetrix

• Biomarker novelty & technology platform
  • Figure 13: Affymetrix' approach to biomarker discovery, validation and clinical utility applications
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Beckman Coulter

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Berkeley HeartLab

• Biomarker novelty & technology platform
  • Figure 14: Markers of cardiovascular disease measured at Berkeley HeartLab
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

BG Medicine

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
  • Figure 15: BG Medicine' s Biomarker Programme
• Application & market potential
• Biomarker analysis

CardioDx

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis
  • Competitor Ratio Analysis Score = 9/40

Celera

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

CIS Biotech

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Clinical Data

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Compugen

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Critical Diagnostics

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

deCODE Genetics

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
  • Figure 16: deCODE' s approach to target discovery and development
• Application & market potential
• Biomarker analysis

diaDexus

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Entelos

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

FoxHollow Technologies

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

GE Healthcare

• Biomarker novelty & technology platform
  • Figure 17: Cardiology focus at GE Healthcare
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Genomas

• Biomarker novelty & technology platform
  • Figure 18: PhysioGenomics Technology from Genomas
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Inverness Medical Innovations

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Jurilab

• Biomarker novelty & technology platform
  • Figure 19: Jurilab' s Genetic Discovery Method
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis
  • Competitor Ratio Analysis Score = 12/40

Laboratory Corporation of America

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Lipomics Technologies

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

LipoScience

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis
  • Competitor Ratio Analysis Score = 15/40

Nanosphere Inc

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Osmetech Molecular Diagnostics

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis
  • Competitor Ratio Analysis Score = 12/40

PrognostiX

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Quest Diagnostics

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis
  • Competitor Ratio Analysis Score = 27/40

Roche Diagnostics

• Biomarker novelty & technology platform
  • Figure 20: Roche' s technologies for biomarker discovery and development
• Association studies/clinical data
  • Figure 21: Roche' s clinical trial programme for cardiac biomarker NT-proBNP
• Management strategy
• Application & market potential
• Biomarker analysis

Siemens Medical Solutions

• Biomarker novelty & technology platform
  • Figure 22: Siemens Integrated in vivo & in vitro diagnostic suites
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Singulex

• Biomarker novelty & technology platform
  • Figure 23: Sensitivity of Singulex' s Erenna system compared to ELISA and bead-based fluorescence readout systems
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

SuperArray Bioscience Corporation

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Vermillion

• Biomarker novelty & technology platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Zora Biosciences OY

• Biomarker novelty & technology platform
  • Table 8: Zora metabolite profiling platform
• Association studies/clinical data
• Management strategy
• Application & market potential
• Biomarker analysis

Cardiovascular biomarker APPENDIX 1

• Table 9: Global biomarker sales 2007-20015E

Cardiovascular biomarker APPENDIX 2

• Table 10: Global cardiovascular biomarker sales 2007-20015E

Cardiovascular biomarker APPENDIX 3

• Company Analysis Criteria
• Biomarker technology & platforms
• Association studies
• Management strategy
• Application & potential
  • Table 9: Key cardiovascular biomarker companies
  • Figure 26: Leading Cardiovascular Biomarker Companies - Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers

GLOSSARY

ACRONYMS

BIBLIOGRAPHY & end NOTES